Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism (ZA-003Ext)

This study has been completed.

Sponsor:

Repros Therapeutics Inc.

ClinicalTrials.gov Identifier:

NCT01067365

First Posted: February 11, 2010

Last Update Posted: June 27, 2014

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.